Published in Psychopharmacology (Berl) on August 01, 2001
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data. Psychopharmacology (Berl) (2003) 1.66
Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol (2008) 1.41
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci (2013) 1.28
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol (2011) 1.27
The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci (2005) 1.20
Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur J Pharmacol (2009) 1.18
Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology (Berl) (2007) 1.18
Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology (Berl) (2005) 1.16
Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) (2006) 1.10
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther (2011) 1.08
Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res (2007) 1.07
Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacology (Berl) (2009) 1.02
Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav (2005) 1.01
Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) (2008) 1.00
Role of training dose in drug discrimination: a review. Behav Pharmacol (2011) 0.99
Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int Rev Psychiatry (2009) 0.98
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther (2013) 0.97
Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology (Berl) (2011) 0.92
Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther (2013) 0.92
Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356). Psychopharmacology (Berl) (2006) 0.92
Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog. Psychopharmacology (Berl) (2008) 0.88
Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology (Berl) (2008) 0.88
The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys. Br J Pharmacol (2011) 0.87
Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacology (Berl) (2004) 0.87
Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. Eur J Pharmacol (2014) 0.87
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl) (2006) 0.86
Quantification of rimonabant (SR 141716A) in monkey plasma using HPLC with UV detection. J Chromatogr Sci (2010) 0.86
Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle. Behav Pharmacol (2011) 0.86
Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats. Psychopharmacology (Berl) (2013) 0.85
The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. Eur J Pharmacol (2011) 0.85
Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology (Berl) (2011) 0.84
Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Curr Addict Rep (2014) 0.83
Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats. Eur J Pharmacol (2010) 0.83
Drug addiction. Curr Top Behav Neurosci (2009) 0.81
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat (2009) 0.81
Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride. Neuropharmacology (2011) 0.80
Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. Neuropharmacology (2015) 0.79
Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg. Psychopharmacology (Berl) (2016) 0.78
[INCREMENT]9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats. Behav Pharmacol (2016) 0.78
Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation. Psychopharmacology (Berl) (2008) 0.77
[Future medications for tobacco and cannabis dependence]. Bull Acad Natl Med (2008) 0.75
Apparent CB1 receptor rimonabant affinity estimates: combination with THC and synthetic cannabinoids in the mouse in vivo triad model. J Pharmacol Exp Ther (2017) 0.75
Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (1987) 6.58
Evaluation of coliform tests for chlorinated secondary effluents. J Water Pollut Control Fed (1973) 5.51
Synthetic lac operator DNA is functional in vivo. Nature (1976) 5.36
The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol (1989) 4.30
HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J (2000) 4.11
Presence of an SH2 domain in the actin-binding protein tensin. Science (1991) 4.03
Dynamics and segregation of cell-matrix adhesions in cultured fibroblasts. Nat Cell Biol (2000) 3.99
The general affinity of lac repressor for E. coli DNA: implications for gene regulation in procaryotes and eucaryotes. Cell (1975) 3.73
Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry (1996) 3.65
Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem (1996) 3.63
T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A (1998) 3.61
Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J Biol Chem (1980) 3.49
Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 3.16
Integrin dynamics and matrix assembly: tensin-dependent translocation of alpha(5)beta(1) integrins promotes early fibronectin fibrillogenesis. J Cell Biol (2000) 3.13
Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol In Vitro (2014) 3.10
Beta-galactosidase. Rates of synthesis and degradation of incomplete chains. J Biol Chem (1972) 3.06
Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker's syndrome. Exp Neurol (1989) 3.00
An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-L-arabinose to lipid A: induction on polymyxin-resistant mutants and role of a novel lipid-linked donor. J Biol Chem (2001) 2.95
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med (1999) 2.92
Cytochalasins inhibit nuclei-induced actin polymerization by blocking filament elongation. J Cell Biol (1980) 2.74
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 2.73
Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 2.71
Cytochalasin B, its interaction with actin and actomyosin from muscle (cell movement-microfilaments-rabbit striated muscle). Proc Natl Acad Sci U S A (1972) 2.68
Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change. Nature (1981) 2.63
The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut (1999) 2.60
Lipid A modifications characteristic of Salmonella typhimurium are induced by NH4VO3 in Escherichia coli K12. Detection of 4-amino-4-deoxy-L-arabinose, phosphoethanolamine and palmitate. J Biol Chem (1999) 2.56
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
GATA-1 expression pattern can be recapitulated in living transgenic zebrafish using GFP reporter gene. Development (1997) 2.38
Specific interaction of vinculin with alpha-actinin. Biochem Biophys Res Commun (1987) 2.34
A comparison of lac repressor binding to operator and to nonoperator DNA. Biochem Biophys Res Commun (1975) 2.32
Lipid A modifications in polymyxin-resistant Salmonella typhimurium: PMRA-dependent 4-amino-4-deoxy-L-arabinose, and phosphoethanolamine incorporation. J Biol Chem (2001) 2.30
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J (1998) 2.29
Bacterial activity in South Pole snow. Appl Environ Microbiol (2000) 2.28
Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J (1997) 2.26
Toward a resolution of the introns early/late debate: only phase zero introns are correlated with the structure of ancient proteins. Proc Natl Acad Sci U S A (1998) 2.16
The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol (2001) 2.15
Zebrafish pigmentation mutations and the processes of neural crest development. Development (1996) 2.14
Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion. Mol Biol Cell (1999) 2.10
Purification and initial characterization of a protein from skeletal muscle that caps the barbed ends of actin filaments. J Biol Chem (1986) 2.08
Neurological impairment in violent schizophrenic inpatients. Am J Psychiatry (1989) 2.07
Neuropathology in mice expressing human alpha-synuclein. J Neurosci (2000) 2.06
Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity (1997) 2.04
Actin polymerization induced by a motility-related high-affinity cytochalasin binding complex from human erythrocyte membrane. Proc Natl Acad Sci U S A (1979) 1.99
Timing, propagation, coordination, and effect of esophageal shortening during peristalsis. Gastroenterology (1997) 1.94
Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms. J Clin Invest (1988) 1.93
The RAD50 gene, a member of the double strand break repair epistasis group, is not required for spontaneous mitotic recombination in yeast. Curr Genet (1990) 1.93
Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen. Nat Biotechnol (1998) 1.92
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Instant MR labeling of stem cells using magnetoelectroporation. Magn Reson Med (2005) 1.88
Biochemical studies on the mode of action of cytochalasin B. Cytochalasin B binding to red cell membrane in relation to glucose transport. J Biol Chem (1974) 1.86
High-affinity interaction of vinculin with actin filaments in vitro. Cell (1982) 1.83
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol (1997) 1.80
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol (1996) 1.78
Pretreatment dropout as a function of treatment delay and client variables. Addict Behav (1995) 1.77
Oxygen requirement for the biosynthesis of the S-2-hydroxymyristate moiety in Salmonella typhimurium lipid A. Function of LpxO, A new Fe2+/alpha-ketoglutarate-dependent dioxygenase homologue. J Biol Chem (2000) 1.76
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
The 200-MeV proton therapy project at the Paul Scherrer Institute: conceptual design and practical realization. Med Phys (1995) 1.75
Biphasic calcium phosphate bioceramics: preparation, properties and applications. J Mater Sci Mater Med (2003) 1.74
Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. Curr Opin Lipidol (2001) 1.70
Closure mechanisms of laryngeal vestibule during swallow. Am J Physiol (1992) 1.67
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature (2001) 1.65
Outcome in schizophrenia and related disorders compared between developing and developed countries. A recursive partitioning re-analysis of the WHO DOSMD data. Br J Psychiatry (1997) 1.65
Experimental characterization and physical modelling of the dose distribution of scanned proton pencil beams. Phys Med Biol (2005) 1.64
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry (2012) 1.63
Shape, volume, and content of the deglutitive pharyngeal chamber imaged by ultrafast computerized tomography. Gastroenterology (1993) 1.63
A zebrafish model for hepatoerythropoietic porphyria. Nat Genet (1998) 1.62
Specificity of the effects of cytochalasin B on transport and motile processes. Proc Natl Acad Sci U S A (1978) 1.61
Accumulation of a polyisoprene-linked amino sugar in polymyxin-resistant Salmonella typhimurium and Escherichia coli: structural characterization and transfer to lipid A in the periplasm. J Biol Chem (2001) 1.60
Reinforcing operants other than abstinence in drug abuse treatment: an effective alternative for reducing drug use. J Consult Clin Psychol (1997) 1.59
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology (2001) 1.58
Synthesis of Sch 29482--a novel penem antibiotic. J Antimicrob Chemother (1982) 1.57
Pharyngeal clearance during swallowing: a combined manometric and videofluoroscopic study. Gastroenterology (1992) 1.56
Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem (1995) 1.52
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
Vascular endothelial growth factor (VEGF) expression and the effect of exogenous VEGF on survival of a random flap in the rat. Br J Plast Surg (2003) 1.50
Modification of bacterial artificial chromosomes through chi-stimulated homologous recombination and its application in zebrafish transgenesis. Proc Natl Acad Sci U S A (1998) 1.49
Intensity modulated proton therapy: a clinical example. Med Phys (2001) 1.49
A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci U S A (1999) 1.49
Promoter analysis in living zebrafish embryos identifies a cis-acting motif required for neuronal expression of GATA-2. Proc Natl Acad Sci U S A (1997) 1.47
Reconstitution of interactions between tyrosine kinases and the high affinity IgE receptor which are controlled by receptor clustering. EMBO J (1995) 1.46
Direct observation of sub-picosecond equilibration of excitation energy in the light-harvesting antenna of Rhodospirillum rubrum. Biophys J (1995) 1.46
High affinity cytochalasin B binding to red cell membrane proteins which are unrelated to sugar transport. J Biol Chem (1977) 1.46
AM630, a competitive cannabinoid receptor antagonist. Life Sci (1995) 1.46
Beta-galactosidase: alpha-complementation of a deletion mutant with cyanogen bromide peptides. Biochem Biophys Res Commun (1970) 1.46
Dihydrocytochalasin B. Biological effects and binding to 3T3 cells. J Cell Biol (1978) 1.45
Trends in blind and low vision registrations in Taipei City. Eur J Ophthalmol (2008) 1.45
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol (2003) 1.44
An alternative to DRGs. A clinically meaningful and cost-reducing approach. Med Care (1986) 1.44
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem (1999) 1.44
Pregnancy outcome following genetic amniocentesis at 11-14 versus 16-19 weeks' gestation. Obstet Gynecol (1996) 1.44
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44